Formerly known as Goodwin Biotechnology, GBI BioManufacturing has proudly announced the execution of its second Master Supply Agreement (MSA) to bring a radioimmunoconjugate product to the commercial market.
Darrin Schellin, CEO of GBI, expressed excitement about the achievement, stating, "We are delighted to unveil the signing of our second commercial contract, a clear reflection of the remarkable capabilities and steadfast dedication of the entire GBI team. This milestone underscores our proficiency and extensive experience in the radiopharmaceutical sector, underscoring the trust our clients place in us."
As the demand for radiopharmaceuticals continues its upward trajectory, GBI is well-positioned to meet industry needs, having made substantial investments in state-of-the-art development and manufacturing capabilities.
Karl Pinto, Chairman of the Board at GBI, shared his satisfaction with the growing trust from clients, saying, "We are pleased to witness more clients relying on us for their long-term commercial product requirements. This announcement is a testament to the robust, enduring, and strategic partnership we have with this rapidly expanding global radiopharmaceutical leader. The radiopharmaceutical sector is experiencing unprecedented growth, and GBI takes pride in being a trailblazer in this transformative industry."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!